Table 1.
Demographics and Clinico-radiological Characteristics
| RRMS | SPMS | PPMS | HCs | |
|---|---|---|---|---|
|
| ||||
| Baseline Demographics | ||||
| n (eyes) | 123 (246) | 25 (50) | 16 (32) | 60 (120) |
| Age (SD) | 39·6 (10·7) | 55·9 (5·5) | 55·7 (6·8) | 36·8 (9·6) |
| Female, n (%) | 92 (75%) | 17 (68%) | 9 (56%) | 39 (65%) |
| Follow-up time in months (SD) | 25·2 (9·5) | 28·5 (6·9) | 26·4 (7·8) | 22·4 (11·4) |
|
| ||||
| Baseline Clinico-Radiological Characteristics | ||||
| ON eyes (%) | 83 (33·7%) | 11 (22%) | 0 (0%) | |
| EDSS, median (range) | 2·0 (0–6·5) | 6·0 (2·5–8.0) | 6·0 (2·5–6·5) | |
| Disease Duration in years (SD) | 8·2 (6·7) | 21·3 (8·1) | 11·9 (8·9) | |
| MSSS, median (range) | 3·34 (0.13–9·47) | 5·16 (1·69–9.2) | 6·74 (1·28–9·08) | |
| Baseline Gd-enhancing lesions1 (%) | 14 (18%) | 0 (0%) | 0 (0%) | |
|
| ||||
| Longitudinal Clinico-Radiological Characteristics | ||||
| Non-ocular relapse, n (%) | 35 (28%) | 0 (0%) | 0 (0%) | |
| EDSS progression2,3, n (%) | 38 (32%) | 4 (16%) | 2 (13%) | |
| New Gd-enhancing lesion4, n (%) | 24 (20%) | 1 (4%) | 2 (14%) | |
| New T2 lesion4, n (%) | 46 (38%) | 3 (13%) | 1 (7%) | |
| Relapse or New Gd-enhancing lesion3, n (%) | 47 (39%) | 1 (4%) | 2 (14%) | |
Data presented above represent means, with their corresponding standard deviation (SD), unless otherwise noted.
RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; HCs: healthy controls; ON: optic neuritis; EDSS: expanded disability status scale; MSSS: multiple sclerosis severity score; Gd: gadolinium
1
Available for 76 RRMS, 19 SPMS and 13 PPMS patients
2
EDSS progression defined as a ≥ 1-point increase if EDSS < 6·0 and a ≥ 0·5 point increase if EDSS ≥ 6·0
3
Available for 120 RRMS, 25 SPMS and 15 PPMS patients
4
Available for 121 RRMS, 24 SPMS and 14 PPMS patients